ANDA 209969, held by Avet Lifesciences. Doxycycline Hyclate.
As of Nov 16, 2026, ANDA 209969 (Doxycycline Hyclate), held by Avet Lifesciences, was first approved by FDA on Nov 9, 2018, with 1 approved supplement and 0 published complete response letters.
| Date | Submission | Status | Documents |
|---|---|---|---|
| Nov 9, 2018 | Original application | Approved | None posted |
| Product | Active ingredient | Marketing |
|---|---|---|
| Doxycycline HyclateEQ 100MG BASE · tablet;oral | Doxycycline Hyclate | Discontinued |
| Mar 31, 2025 | Supplement 1Labeling · Standard review | Approved | None posted |
| Nov 9, 2018 | Original application | Approved | None posted |
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. Drugs@FDA and FDA complete response letters